ketamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1523 6740-88-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketamine
  • narketan
  • (+/-)-Ketamine
  • ketamine hydrochloride
  • ketamine HCl
A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
  • Molecular weight: 237.73
  • Formula: C13H16ClNO
  • CLOGP: 2.93
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.10
  • ALOGS: -3.71
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 200 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.41 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.47 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 19, 1970 FDA PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 596.75 24.78 205 11149 23428 63454240
Drug ineffective for unapproved indication 172.40 24.78 95 11259 33968 63443700
Propofol infusion syndrome 171.92 24.78 39 11315 944 63476724
Body tinea 170.77 24.78 44 11310 1841 63475827
Inhibitory drug interaction 148.32 24.78 43 11311 2806 63474862
Infection susceptibility increased 143.57 24.78 44 11310 3477 63474191
Dilatation intrahepatic duct acquired 140.66 24.78 31 11323 655 63477013
Multiple-drug resistance 138.66 24.78 47 11307 5123 63472545
Bronchospasm 133.21 24.78 64 11290 17216 63460452
Mitochondrial DNA mutation 131.86 24.78 27 11327 395 63477273
Oesophageal spasm 127.22 24.78 39 11315 3084 63474584
Oesophageal pain 120.70 24.78 39 11315 3662 63474006
Hydronephrosis 118.62 24.78 51 11303 10611 63467057
Glucose tolerance impaired 116.62 24.78 44 11310 6533 63471135
Intra-abdominal pressure increased 114.52 24.78 22 11332 227 63477441
Drug ineffective 108.66 24.78 419 10935 1044346 62433322
Poor quality sleep 104.69 24.78 57 11297 19878 63457790
Hypotension 104.64 24.78 180 11174 272424 63205244
Drug abuse 99.54 24.78 91 11263 72427 63405241
Anaphylactic reaction 94.74 24.78 85 11269 66015 63411653
Respiratory depression 94.33 24.78 47 11307 13668 63464000
Purpura 93.33 24.78 44 11310 11341 63466327
Blood lactic acid increased 92.56 24.78 38 11316 7048 63470620
Impaired quality of life 91.17 24.78 46 11308 13737 63463931
Pneumatosis 91.08 24.78 20 11334 415 63477253
Blood gases abnormal 89.03 24.78 22 11332 775 63476893
Necrosis ischaemic 87.36 24.78 22 11332 838 63476830
Biliary dilatation 86.78 24.78 27 11327 2242 63475426
Status epilepticus 84.01 24.78 45 11309 15188 63462480
Bone density decreased 82.93 24.78 44 11310 14568 63463100
Sterile pyuria 81.83 24.78 12 11342 15 63477653
Gene mutation 81.67 24.78 24 11330 1641 63476027
Impaired work ability 80.91 24.78 46 11308 17429 63460239
Unwanted awareness during anaesthesia 78.94 24.78 17 11337 321 63477347
Lymphoedema 77.26 24.78 39 11315 11653 63466015
Arthralgia 76.54 24.78 7 11347 569703 62907965
Agitation 76.21 24.78 72 11282 59685 63417983
Delirium 74.40 24.78 66 11288 50475 63427193
Off label use 74.16 24.78 276 11078 674186 62803482
Hypercapnia 73.92 24.78 30 11324 5401 63472267
Cardio-respiratory arrest 72.21 24.78 70 11284 59889 63417779
Blood pH decreased 71.26 24.78 24 11330 2563 63475105
Hyperlipidaemia 70.96 24.78 44 11310 19527 63458141
CSF oligoclonal band present 70.65 24.78 16 11338 384 63477284
Reduced bladder capacity 68.67 24.78 9 11345 0 63477668
Intestinal ischaemia 64.73 24.78 30 11324 7438 63470230
Hyperaesthesia 64.14 24.78 32 11322 9326 63468342
Shock 63.67 24.78 44 11310 23419 63454249
Allergy test negative 63.43 24.78 13 11341 191 63477477
Cardiac arrest 62.78 24.78 80 11274 92465 63385203
Oral herpes 61.75 24.78 45 11309 26029 63451639
Bladder hypertrophy 61.32 24.78 13 11341 227 63477441
Intestinal infarction 59.80 24.78 17 11337 1033 63476635
Systemic inflammatory response syndrome 59.61 24.78 26 11328 5595 63472073
Skin disorder 58.95 24.78 46 11308 29461 63448207
Pleocytosis 58.76 24.78 16 11338 829 63476839
Type I hypersensitivity 56.97 24.78 21 11333 2921 63474747
Respiratory acidosis 55.18 24.78 26 11328 6689 63470979
Biliary tract disorder 54.45 24.78 15 11339 812 63476856
Venoocclusive liver disease 53.35 24.78 23 11331 4812 63472856
Local anaesthetic systemic toxicity 53.21 24.78 15 11339 884 63476784
Airway peak pressure increased 53.18 24.78 12 11342 283 63477385
Partial seizures 52.29 24.78 24 11330 5818 63471850
Cystitis 51.34 24.78 56 11298 54935 63422733
Hepatocellular injury 51.08 24.78 41 11313 27340 63450328
Contracted bladder 50.91 24.78 7 11347 3 63477665
Stress cardiomyopathy 49.54 24.78 27 11327 9423 63468245
Metabolic acidosis 49.39 24.78 50 11304 45019 63432649
Headache 49.33 24.78 26 11328 633215 62844453
Sleep apnoea syndrome 48.85 24.78 41 11313 29092 63448576
Cholestasis 48.48 24.78 41 11313 29393 63448275
PCO2 increased 48.46 24.78 15 11339 1224 63476444
Acute generalised exanthematous pustulosis 48.12 24.78 28 11326 11071 63466597
Lung hyperinflation 47.80 24.78 15 11339 1280 63476388
Ultrasound ovary abnormal 47.29 24.78 9 11345 88 63477580
Tachycardia 46.46 24.78 79 11275 118077 63359591
Anaphylactoid shock 46.34 24.78 11 11343 326 63477342
Abdominal discomfort 45.66 24.78 3 11351 320882 63156786
Tinnitus 45.53 24.78 43 11311 35585 63442083
Miosis 44.15 24.78 23 11331 7330 63470338
PO2 decreased 41.59 24.78 14 11340 1492 63476176
Blood creatine phosphokinase increased 41.34 24.78 38 11316 30392 63447276
Perforation 40.76 24.78 13 11341 1170 63476498
Alopecia 40.64 24.78 6 11348 337530 63140138
Status asthmaticus 39.85 24.78 12 11342 892 63476776
Lower urinary tract symptoms 39.79 24.78 7 11347 42 63477626
Ureteric stenosis 39.49 24.78 11 11343 620 63477048
Tonic clonic movements 38.29 24.78 13 11341 1422 63476246
Ureteral polyp 38.15 24.78 5 11349 0 63477668
Cystitis ulcerative 38.15 24.78 5 11349 0 63477668
Intensive care unit acquired weakness 36.63 24.78 11 11343 810 63476858
Hallucination 36.53 24.78 47 11307 54770 63422898
Immune thrombocytopenia 36.41 24.78 23 11331 10533 63467135
Nausea 36.17 24.78 61 11293 854410 62623258
Arrhythmia 35.87 24.78 39 11315 38101 63439567
Blood bicarbonate decreased 35.79 24.78 15 11339 2926 63474742
Diastolic hypotension 35.02 24.78 7 11347 90 63477578
Renal infarct 34.31 24.78 12 11342 1435 63476233
Sedation 33.59 24.78 38 11316 38771 63438897
Generalised tonic-clonic seizure 33.27 24.78 33 11321 28983 63448685
Intensive care unit delirium 32.38 24.78 6 11348 50 63477618
Encephalitis 32.27 24.78 20 11334 8860 63468808
Bladder disorder 32.13 24.78 20 11334 8926 63468742
Bladder necrosis 32.03 24.78 5 11349 12 63477656
Post procedural stroke 31.87 24.78 6 11348 55 63477613
Drug intolerance 31.85 24.78 8 11346 308653 63169015
Drug use disorder 31.10 24.78 16 11338 4968 63472700
Cataract 30.56 24.78 44 11310 57009 63420659
Reversible cerebral vasoconstriction syndrome 30.50 24.78 13 11341 2645 63475023
Pain 30.27 24.78 54 11300 740574 62737094
Left ventricular hypertrophy 30.13 24.78 16 11338 5299 63472369
Bradypnoea 29.95 24.78 14 11340 3536 63474132
Hepatotoxicity 29.92 24.78 35 11319 37006 63440662
Euthyroid sick syndrome 29.89 24.78 6 11348 79 63477589
Nasopharyngitis 29.50 24.78 5 11349 254252 63223416
Drug withdrawal syndrome 29.48 24.78 30 11324 27164 63450504
Rheumatoid arthritis 29.43 24.78 5 11349 253814 63223854
Cystitis interstitial 29.38 24.78 11 11343 1597 63476071
Urinary tract disorder 29.23 24.78 13 11341 2928 63474740
Peripheral swelling 29.21 24.78 6 11348 265936 63211732
Decreased appetite 28.99 24.78 5 11349 251047 63226621
Mucocutaneous haemorrhage 28.97 24.78 6 11348 93 63477575
Bradycardia 28.81 24.78 49 11305 73178 63404490
Swelling 28.67 24.78 7 11347 275371 63202297
Oxygen saturation decreased 28.13 24.78 54 11300 88531 63389137
Tachyphylaxis 27.73 24.78 7 11347 269 63477399
Fluid retention 27.64 24.78 43 11311 59643 63418025
Toxicity to various agents 26.79 24.78 101 11253 247149 63230519
Cyanosis 26.68 24.78 23 11331 16912 63460756
Drug dependence 26.52 24.78 27 11327 24456 63453212
Product dose omission issue 26.33 24.78 5 11349 234308 63243360
Posterior reversible encephalopathy syndrome 26.20 24.78 23 11331 17322 63460346
Cellulitis 26.07 24.78 50 11304 81908 63395760
Infusion related reaction 26.03 24.78 6 11348 245515 63232153
Ureteral disorder 25.99 24.78 7 11347 348 63477320
Cough 25.88 24.78 10 11344 292733 63184935
Poisoning deliberate 25.74 24.78 19 11335 11199 63466469

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 536.34 22.31 195 10197 15746 34930793
Drug abuse 200.54 22.31 193 10199 98903 34847636
Drug ineffective 192.87 22.31 419 9973 456332 34490207
Sedation 186.80 22.31 101 10291 20905 34925634
Nightmare 144.32 22.31 75 10317 14316 34932223
Cystitis ulcerative 128.20 22.31 18 10374 0 34946539
Hypotension 124.72 22.31 230 10162 221419 34725120
Anaphylactic reaction 95.21 22.31 78 10314 32223 34914316
Product used for unknown indication 91.02 22.31 26 10366 957 34945582
Nephrolithiasis 90.98 22.31 74 10318 30259 34916280
Bradycardia 89.35 22.31 111 10281 75307 34871232
Bronchospasm 82.72 22.31 47 10345 10684 34935855
Hydronephrosis 81.60 22.31 46 10346 10300 34936239
Tachycardia 79.13 22.31 111 10281 84661 34861878
Hyperaesthesia 76.46 22.31 34 10358 4596 34941943
Sedation complication 75.86 22.31 26 10366 1751 34944788
Off label use 74.84 22.31 283 10109 419241 34527298
Biopsy bladder abnormal 71.22 22.31 10 10382 0 34946539
Cystitis 65.28 22.31 39 10353 9726 34936813
Cystitis interstitial 64.39 22.31 14 10378 161 34946378
Delirium 64.06 22.31 72 10320 43919 34902620
Agitation 63.99 22.31 82 10310 57317 34889222
Behaviour disorder 62.19 22.31 30 10362 4880 34941659
Reduced bladder capacity 61.51 22.31 9 10383 3 34946536
Respiratory depression 60.35 22.31 45 10347 16200 34930339
Drug screen positive 58.90 22.31 27 10365 3916 34942623
Product use in unapproved indication 52.55 22.31 111 10281 117388 34829151
Drug dependence 52.26 22.31 49 10343 24168 34922371
Delayed recovery from anaesthesia 51.57 22.31 16 10376 785 34945754
Cardiac arrest 51.56 22.31 98 10294 96061 34850478
Anal inflammation 51.54 22.31 18 10374 1282 34945257
Allergy test negative 51.12 22.31 11 10381 120 34946419
Hyperhidrosis 50.66 22.31 85 10307 75607 34870932
Contracted bladder 50.06 22.31 8 10384 11 34946528
Diabetes insipidus 49.95 22.31 22 10370 2906 34943633
Mydriasis 48.62 22.31 29 10363 7208 34939331
Toxicity to various agents 48.50 22.31 150 10242 200212 34746327
Cholestasis 46.03 22.31 48 10344 26900 34919639
Fatigue 45.55 22.31 27 10365 370626 34575913
Drug ineffective for unapproved indication 45.53 22.31 45 10347 23670 34922869
SARS-CoV-2 test negative 43.83 22.31 15 10377 1005 34945534
Pulseless electrical activity 43.57 22.31 27 10365 7184 34939355
Dyspnoea 42.81 22.31 30 10362 376752 34569787
Metabolic acidosis 41.89 22.31 58 10334 43622 34902917
Pneumonia 39.72 22.31 30 10362 362597 34583942
Propofol infusion syndrome 36.86 22.31 13 10379 953 34945586
Miosis 36.72 22.31 27 10365 9508 34937031
Hypercapnia 36.50 22.31 20 10372 4235 34942304
Abdominal compartment syndrome 33.24 22.31 12 10380 941 34945598
Biliary dilatation 32.70 22.31 12 10380 986 34945553
Diarrhoea 32.58 22.31 41 10351 389871 34556668
Hypoventilation 31.94 22.31 17 10375 3397 34943142
Circulatory collapse 31.57 22.31 35 10357 21003 34925536
Intentional product misuse 31.53 22.31 52 10340 45559 34900980
Hyperammonaemia 31.45 22.31 21 10371 6346 34940193
Drug use disorder 31.33 22.31 18 10374 4173 34942366
Accidental death 31.08 22.31 15 10377 2441 34944098
Hyperarousal 31.06 22.31 6 10386 36 34946503
Accident 30.75 22.31 19 10373 5028 34941511
Anaphylactoid shock 30.33 22.31 9 10383 379 34946160
Wolff-Parkinson-White syndrome 30.31 22.31 8 10384 218 34946321
Substance abuse 30.24 22.31 22 10370 7619 34938920
Rhabdomyolysis 29.96 22.31 64 10328 68099 34878440
Urinary tract disorder 29.41 22.31 14 10378 2210 34944329
Hypoxia 29.30 22.31 56 10336 55039 34891500
Disorientation 28.76 22.31 42 10350 33146 34913393
Biliary tract disorder 28.63 22.31 11 10381 1027 34945512
Anaemia 28.59 22.31 17 10375 233318 34713221
Ureteral polyp 28.49 22.31 4 10388 0 34946539
Hypertonia 28.48 22.31 17 10375 4229 34942310
Airway complication of anaesthesia 28.12 22.31 7 10385 150 34946389
Aggression 27.71 22.31 45 10347 38919 34907620
Cholangiolitis 27.57 22.31 5 10387 20 34946519
Bladder disorder 26.88 22.31 15 10377 3289 34943250
Haematuria traumatic 26.48 22.31 7 10385 192 34946347
Axillary pain 26.14 22.31 8 10384 375 34946164
Apnoea 25.95 22.31 19 10373 6645 34939894
Type I hypersensitivity 25.91 22.31 11 10381 1328 34945211
Asthenia 25.90 22.31 21 10371 245230 34701309
Neonatal hypoxia 25.66 22.31 8 10384 399 34946140
Brief psychotic disorder with marked stressors 25.44 22.31 7 10385 224 34946315
Coma 24.99 22.31 47 10345 45631 34900908
Laryngospasm 24.57 22.31 11 10381 1510 34945029
Headache 24.04 22.31 15 10377 200620 34745919
Paradoxical drug reaction 24.01 22.31 14 10378 3337 34943202
Diastolic hypertension 23.91 22.31 5 10387 47 34946492
Complication of device removal 23.28 22.31 5 10387 54 34946485
Myocardial infarction 23.26 22.31 4 10388 121081 34825458
Cardio-respiratory arrest 23.25 22.31 51 10341 55222 34891317
Drug tolerance 23.22 22.31 13 10379 2869 34943670
Transcranial electrical motor evoked potential monitoring abnormal 22.94 22.31 4 10388 12 34946527
Multiple-drug resistance 22.84 22.31 16 10376 5223 34941316
Anaesthetic complication neurological 22.79 22.31 7 10385 332 34946207
Chest pain 22.64 22.31 5 10387 126757 34819782

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 1102.69 18.94 398 20595 35598 79687797
Drug abuse 288.01 18.94 279 20714 162412 79560983
Drug ineffective 279.70 18.94 763 20230 1080150 78643245
Hypotension 213.30 18.94 400 20593 439917 79283478
Bronchospasm 204.39 18.94 109 20884 24750 79698645
Hydronephrosis 197.54 18.94 95 20898 17359 79706036
Propofol infusion syndrome 187.85 18.94 52 20941 1931 79721464
Drug ineffective for unapproved indication 187.50 18.94 134 20859 51104 79672291
Anaphylactic reaction 175.67 18.94 158 20835 83585 79639810
Cystitis ulcerative 166.59 18.94 23 20970 0 79723395
Sedation 154.68 18.94 120 20873 51775 79671620
Body tinea 150.11 18.94 43 20950 1811 79721584
Agitation 132.84 18.94 147 20846 99568 79623827
Reduced bladder capacity 130.38 18.94 18 20975 0 79723395
Hyperaesthesia 127.70 18.94 63 20930 12159 79711236
Respiratory depression 121.63 18.94 81 20912 27549 79695846
Multiple-drug resistance 121.53 18.94 55 20938 8753 79714642
Off label use 121.41 18.94 515 20478 906700 78816695
Mitochondrial DNA mutation 120.75 18.94 27 20966 406 79722989
Infection susceptibility increased 120.64 18.94 43 20950 3678 79719717
Oesophageal spasm 119.90 18.94 42 20951 3414 79719981
Arthralgia 119.54 18.94 8 20985 571795 79151600
Biliary dilatation 116.74 18.94 39 20954 2747 79720648
Tachycardia 113.79 18.94 183 20810 177585 79545810
Dilatation intrahepatic duct acquired 111.39 18.94 28 20965 710 79722685
Oesophageal pain 111.15 18.94 42 20951 4237 79719158
Cardiac arrest 109.92 18.94 177 20816 171919 79551476
Inhibitory drug interaction 109.52 18.94 42 20951 4411 79718984
Bradycardia 107.20 18.94 154 20839 135403 79587992
Delirium 106.26 18.94 121 20872 84506 79638889
Allergy test negative 105.14 18.94 23 20970 311 79723084
Intra-abdominal pressure increased 103.46 18.94 22 20971 258 79723137
Hypercapnia 102.19 18.94 49 20944 8886 79714509
Cystitis 101.75 18.94 95 20898 52637 79670758
Nightmare 95.39 18.94 68 20925 25793 79697602
Contracted bladder 91.70 18.94 14 20979 14 79723381
Cholestasis 89.41 18.94 88 20905 52021 79671374
Glucose tolerance impaired 88.42 18.94 43 20950 8041 79715354
Metabolic acidosis 87.10 18.94 108 20885 82421 79640974
Sterile pyuria 83.74 18.94 15 20978 64 79723331
Product used for unknown indication 82.54 18.94 26 20967 1518 79721877
Headache 81.81 18.94 35 20958 653737 79069658
Cystitis interstitial 81.11 18.94 25 20968 1358 79722037
Bladder hypertrophy 79.90 18.94 21 20972 638 79722757
Poor quality sleep 79.81 18.94 58 20935 22664 79700731
Drug dependence 79.71 18.94 74 20919 40695 79682700
Biopsy bladder abnormal 79.67 18.94 11 20982 0 79723395
Miosis 78.57 18.94 50 20943 15739 79707656
Pneumatosis 78.20 18.94 22 20971 867 79722528
Type I hypersensitivity 75.40 18.94 32 20961 4366 79719029
Cardio-respiratory arrest 73.91 18.94 115 20878 108395 79615000
Necrosis ischaemic 73.77 18.94 22 20971 1068 79722327
Shock 71.85 18.94 72 20921 43476 79679919
Anaphylactoid shock 71.77 18.94 20 20973 761 79722634
Behaviour disorder 70.31 18.94 34 20959 6279 79717116
Blood lactic acid increased 70.08 18.94 43 20950 12701 79710694
Respiratory acidosis 69.91 18.94 41 20952 11159 79712236
Lymphoedema 68.55 18.94 42 20951 12371 79711024
Bone density decreased 68.25 18.94 43 20950 13304 79710091
Blood gases abnormal 67.81 18.94 21 20972 1159 79722236
Impaired quality of life 67.74 18.94 44 20949 14342 79709053
Diabetes insipidus 66.90 18.94 31 20962 5206 79718189
Ureteral polyp 65.19 18.94 9 20984 0 79723395
Dyspnoea 64.23 18.94 79 20914 856946 78866449
Status epilepticus 64.12 18.94 53 20940 24988 79698407
CSF oligoclonal band present 63.67 18.94 16 20977 405 79722990
Gene mutation 61.31 18.94 24 20969 2662 79720733
Sedation complication 59.63 18.94 42 20951 15627 79707768
Bladder disorder 58.39 18.94 34 20959 9131 79714264
Unwanted awareness during anaesthesia 57.41 18.94 14 20979 312 79723083
Product use in unapproved indication 57.25 18.94 170 20823 250189 79473206
Biliary tract disorder 56.87 18.94 20 20973 1644 79721751
Urinary tract disorder 56.85 18.94 25 20968 3717 79719678
Drug screen positive 56.71 18.94 29 20964 6034 79717361
Impaired work ability 55.34 18.94 44 20949 19637 79703758
Mydriasis 55.16 18.94 42 20951 17601 79705794
Joint swelling 54.87 18.94 6 20987 288640 79434755
Intensive care unit acquired weakness 53.94 18.94 20 20973 1913 79721482
Purpura 53.51 18.94 43 20950 19484 79703911
Hepatocellular injury 52.97 18.94 64 20929 47529 79675866
Lower urinary tract symptoms 52.56 18.94 12 20981 199 79723196
Drug use disorder 52.24 18.94 31 20962 8620 79714775
Laryngospasm 52.12 18.94 24 20969 3973 79719422
Nephrolithiasis 51.86 18.94 67 20926 53224 79670171
Airway peak pressure increased 51.59 18.94 13 20980 333 79723062
Asthenia 51.43 18.94 36 20957 511653 79211742
Partial seizures 51.17 18.94 31 20962 8947 79714448
Abdominal discomfort 50.88 18.94 4 20989 250723 79472672
Intestinal infarction 49.29 18.94 17 20976 1319 79722076
Delayed recovery from anaesthesia 49.24 18.94 18 20975 1655 79721740
Intestinal ischaemia 49.17 18.94 35 20958 13235 79710160
Diarrhoea 48.99 18.94 99 20894 880390 78843005
Nasopharyngitis 48.96 18.94 5 20988 253876 79469519
Anal inflammation 48.16 18.94 17 20976 1413 79721982
Hyperhidrosis 45.75 18.94 114 20879 151378 79572017
Sleep apnoea syndrome 45.48 18.94 52 20941 36426 79686969
Status asthmaticus 45.42 18.94 15 20978 1019 79722376
Hallucination 45.15 18.94 81 20912 85664 79637731
Local anaesthetic systemic toxicity 45.13 18.94 15 20978 1039 79722356
Pleocytosis 44.28 18.94 16 20977 1423 79721972
Circulatory collapse 44.13 18.94 52 20941 37616 79685779
Hypoxia 43.84 18.94 89 20904 103154 79620241
Ultrasound ovary abnormal 43.81 18.94 9 20984 88 79723307
Peripheral swelling 43.48 18.94 9 20984 269608 79453787
Alopecia 43.48 18.94 5 20988 231350 79492045
Hyperlipidaemia 42.77 18.94 43 20950 26050 79697345
Oral herpes 42.74 18.94 44 20949 27410 79695985
Stress cardiomyopathy 42.65 18.94 30 20963 11136 79712259
Cough 42.15 18.94 22 20971 366767 79356628
Intentional product misuse 41.56 18.94 83 20910 95082 79628313
Hypoventilation 41.32 18.94 25 20968 7199 79716196
SARS-CoV-2 test negative 41.27 18.94 15 20978 1356 79722039
Ureteric stenosis 41.05 18.94 15 20978 1377 79722018
Haemodynamic instability 40.81 18.94 35 20958 17347 79706048
Drug withdrawal syndrome 40.79 18.94 48 20945 34670 79688725
Ureteral disorder 40.67 18.94 12 20981 561 79722834
Rheumatoid arthritis 40.47 18.94 4 20989 208466 79514929
Lung hyperinflation 40.29 18.94 16 20977 1843 79721552
Drug intolerance 40.22 18.94 10 20983 264109 79459286
Decreased appetite 40.15 18.94 20 20973 342398 79380997
Swelling 39.94 18.94 5 20988 216706 79506689
Airway complication of anaesthesia 39.71 18.94 11 20982 409 79722986
Blood pH decreased 39.66 18.94 21 20972 4690 79718705
Chest pain 38.74 18.94 13 20980 282291 79441104
Oedema peripheral 37.56 18.94 10 20983 252278 79471117
Tonic clonic movements 37.24 18.94 16 20977 2248 79721147
Disease progression 37.23 18.94 3 20990 184359 79539036
PCO2 increased 36.98 18.94 15 20978 1825 79721570
Skin disorder 36.71 18.94 45 20948 33898 79689497
Pain in extremity 36.13 18.94 26 20967 364512 79358883
Tinnitus 35.92 18.94 51 20942 44282 79679113
Toxicity to various agents 35.80 18.94 211 20782 421329 79302066
Anaemia 35.40 18.94 39 20954 444976 79278419
Systemic inflammatory response syndrome 35.19 18.94 27 20966 11438 79711957
Anaesthetic complication neurological 35.07 18.94 11 20982 633 79722762
Apnoea 34.70 18.94 27 20966 11677 79711718
Product dose omission issue 34.67 18.94 11 20982 247526 79475869
Venoocclusive liver disease 34.56 18.94 27 20966 11744 79711651
Infusion related reaction 34.51 18.94 9 20984 230228 79493167
Weight decreased 34.34 18.94 26 20967 355172 79368223
Pulseless electrical activity 34.24 18.94 29 20964 14131 79709264
Perforation 33.46 18.94 13 20980 1413 79721982
Withdrawal syndrome 33.00 18.94 38 20955 26816 79696579
Arthropathy 32.85 18.94 4 20989 177107 79546288
Drug abuser 32.32 18.94 20 20973 5993 79717402
Blood creatine phosphokinase increased 31.72 18.94 60 20933 66030 79657365
Coma 31.70 18.94 77 20916 100572 79622823
Dehydration 31.41 18.94 13 20980 248174 79475221
Fall 31.37 18.94 50 20943 487579 79235816
Acute generalised exanthematous pustulosis 31.19 18.94 30 20963 17224 79706171
Substance abuse 30.59 18.94 24 20969 10502 79712893
Accidental death 30.23 18.94 17 20976 4274 79719121
Drug tolerance 30.13 18.94 22 20971 8653 79714742
Intensive care unit delirium 29.56 18.94 6 20987 55 79723340
Rhabdomyolysis 29.44 18.94 76 20917 103055 79620340
Urinary tract infection 29.32 18.94 18 20975 274494 79448901
Paradoxical drug reaction 29.07 18.94 20 20973 7165 79716230
Transcranial electrical motor evoked potential monitoring abnormal 29.04 18.94 5 20988 16 79723379
Wolff-Parkinson-White syndrome 28.95 18.94 8 20985 295 79723100
Bladder necrosis 28.81 18.94 5 20988 17 79723378
Abdominal compartment syndrome 28.64 18.94 12 20981 1585 79721810
Dissociative disorder 28.56 18.94 10 20983 811 79722584
Fatigue 28.54 18.94 137 20856 929590 78793805
Diastolic hypotension 27.86 18.94 7 20986 177 79723218
Haematuria traumatic 27.39 18.94 7 20986 190 79723205
Cholangiolitis 27.26 18.94 5 20988 25 79723370
PO2 decreased 27.21 18.94 14 20979 2949 79720446
Euthyroid sick syndrome 26.85 18.94 6 20987 90 79723305
Hypertonia 26.62 18.94 19 20974 7213 79716182
Hyperarousal 26.49 18.94 5 20988 30 79723365
Dysphoria 26.09 18.94 16 20977 4718 79718677
Antisocial behaviour 25.92 18.94 9 20984 712 79722683
Paralysis 25.90 18.94 24 20969 13153 79710242
Post procedural stroke 25.82 18.94 6 20987 108 79723287
Accident 25.37 18.94 20 20973 8811 79714584
Macroglossia 25.02 18.94 10 20983 1171 79722224
Bradypnoea 24.85 18.94 17 20976 6035 79717360
Acidosis 24.34 18.94 28 20965 19734 79703661
Brief psychotic disorder with marked stressors 24.27 18.94 7 20986 302 79723093
Pyuria 24.19 18.94 12 20981 2340 79721055
Multiple organ dysfunction syndrome 24.05 18.94 78 20915 120168 79603227
Injection site pain 23.90 18.94 3 20990 129835 79593560
Pneumonia 23.44 18.94 92 20901 660154 79063241
Hyperammonaemia 23.36 18.94 21 20972 11072 79712323
Upper airway obstruction 23.19 18.94 10 20983 1418 79721977
General physical health deterioration 23.12 18.94 23 20970 275215 79448180
Myalgia 23.04 18.94 10 20983 185631 79537764
Aggression 22.90 18.94 45 20948 50913 79672482
Cholangitis sclerosing 22.90 18.94 12 20981 2625 79720770
Neuromuscular block prolonged 22.79 18.94 9 20984 1021 79722374
Arrhythmia 22.72 18.94 50 20943 61222 79662173
Renal infarct 22.67 18.94 12 20981 2679 79720716
Pain 22.56 18.94 102 20891 703700 79019695
Depressed level of consciousness 22.39 18.94 66 20927 96586 79626809
Blood bicarbonate decreased 22.31 18.94 15 20978 5176 79718219
Mucocutaneous haemorrhage 22.24 18.94 6 20987 202 79723193
Diastolic hypertension 22.01 18.94 5 20988 81 79723314
Haemoglobin decreased 21.78 18.94 16 20977 222103 79501292
Hepatotoxicity 21.47 18.94 44 20949 51308 79672087
Aplastic anaemia 21.43 18.94 25 20968 17880 79705515
Intentional product misuse to child 21.41 18.94 5 20988 92 79723303
Therapy non-responder 21.35 18.94 63 20930 92242 79631153
Reversible cerebral vasoconstriction syndrome 21.23 18.94 12 20981 3045 79720350
Mania 21.04 18.94 25 20968 18235 79705160
Oxygen saturation decreased 20.85 18.94 78 20915 128969 79594426
Musculoskeletal stiffness 20.83 18.94 10 20983 174998 79548397
Cyanosis 20.44 18.94 29 20964 25153 79698242
Brain oedema 20.37 18.94 29 20964 25234 79698161
Symptom masked 20.19 18.94 9 20984 1381 79722014
Encephalitis 20.04 18.94 22 20971 14738 79708657
Mobility decreased 19.84 18.94 4 20989 122171 79601224
Disorientation 19.73 18.94 48 20945 62728 79660667
Back pain 19.72 18.94 31 20962 304149 79419246
Nystagmus 19.39 18.94 18 20975 9886 79713509

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01AX03 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, GENERAL
Other general anesthetics
MeSH PA D000700 Analgesics
MeSH PA D000777 Anesthetics
MeSH PA D000778 Anesthetics, Dissociative
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:38877 intravenous anesthetics
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:60643 N-methyl-D-aspartate receptor antagonists
CHEBI has role CHEBI:78298 environmental contaminants
FDA EPC N0000175681 General Anesthetic
FDA PE N0000175975 General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Local anesthesia indication 386761002
Pain off-label use 22253000
Inflammatory disease of mucous membrane off-label use 95361005
Major depressive disorder off-label use 370143000
Delirium contraindication 2776000
Ocular hypertension contraindication 4210003 DOID:9282
Alcoholism contraindication 7200002
Myocardial infarction contraindication 22298006 DOID:5844
Alcohol intoxication contraindication 25702006
Hypertensive disorder contraindication 38341003 DOID:10763
Decreased respiratory function contraindication 80954004
Thyrotoxicosis contraindication 90739004 DOID:7997
Acute disease of cardiovascular system contraindication 128487001
Decompensated cardiac failure contraindication 195111005
Cerebrovascular accident contraindication 230690007
Raised intracranial pressure contraindication 271719001 DOID:9428
Cerebral trauma contraindication 275382005
Impaired cognition contraindication 386806002
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000
Psychiatric Disturbance contraindication
Cardiac Decompensation contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Restraint Indication
Cats Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation Indication
Primates Restraint Indication
Primates Anesthesia in diagnostic or minor surgical procedures that do not require skeletal muscle relaxation Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Ketaset Zoetis Inc. 1
Ketaset, Vetalar Boehringer lngelheim Animal Health USA Inc. 1
Ketaset Plus Zoetis Inc. 3
Ketamine Hydrochloride Injection Cronus Pharma Specialities India Private Limited 1
Ketamine Hydrochloride Injection, USP Elanco US Inc. 1
VetaKet Akorn Animal Health Inc. 1
Ketamine Hydrochloride Injection, USP Dechra Veterinary Products LLC 1
Ketamine HCL Mylan Institutional LLC, a Viatris Company 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate [NMDA] receptor Ion channel BLOCKER Ki 6.38 CHEMBL CHEMBL
Glutamate receptor ionotropic AMPA Ion channel OPENER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Acetylcholine receptor subunit alpha Ion channel IC50 5.31 CHEMBL
Glutamate NMDA receptor Ion channel IC50 6.21 CHEMBL

External reference:

IDSource
4019796 VUID
N0000147885 NUI
D00711 KEGG_DRUG
1867-66-9 SECONDARY_CAS_RN
4018154 VANDF
4019796 VANDF
C0022614 UMLSCUI
CHEBI:6121 CHEBI
CHEMBL742 ChEMBL_ID
DB01221 DRUGBANK_ID
CHEMBL1714 ChEMBL_ID
D007649 MESH_DESCRIPTOR_UI
3821 PUBCHEM_CID
4233 IUPHAR_LIGAND_ID
2156 INN_ID
690G0D6V8H UNII
203184 RXNORM
4944 MMSL
9883 MMSL
d00272 MMSL
001403 NDDF
004581 NDDF
31706007 SNOMEDCT_US
333847008 SNOMEDCT_US
373464007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9508 INJECTION 50 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9508 INJECTION 50 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9509 INJECTION 100 mg INTRAMUSCULAR ANDA 27 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9509 INJECTION 100 mg INTRAMUSCULAR ANDA 27 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 0404-9880 INJECTION 10 mg INTRAVENOUS NDA 17 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 0404-9880 INJECTION 10 mg INTRAVENOUS NDA 17 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9881 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9881 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9881 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9882 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 14 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9882 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 14 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-0040 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-0040 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2051 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2051 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2053 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2053 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-682 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-683 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 31 sections
Ketamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-684 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 31 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-113 INJECTION 10 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-113 INJECTION 10 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-114 INJECTION 50 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-114 INJECTION 50 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-115 INJECTION 100 mg INTRAMUSCULAR NDA 27 sections
Ketalar HUMAN PRESCRIPTION DRUG LABEL 1 42023-115 INJECTION 100 mg INTRAMUSCULAR NDA 27 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 52584-037 INJECTION 10 mg INTRAVENOUS NDA 19 sections
KETALAR HUMAN PRESCRIPTION DRUG LABEL 1 52584-037 INJECTION 10 mg INTRAVENOUS NDA 19 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-038 INJECTION, SOLUTION, CONCENTRATE 50 mg INTRAMUSCULAR ANDA 14 sections
KETAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-040 INJECTION, SOLUTION, CONCENTRATE 100 mg INTRAMUSCULAR ANDA 19 sections